Omeros Co. (NASDAQ:OMER) Shares Purchased by Comerica Bank

Comerica Bank boosted its holdings in Omeros Co. (NASDAQ:OMER) by 16.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,000 shares of the biopharmaceutical company’s stock after purchasing an additional 5,000 shares during the quarter. Comerica Bank owned approximately 0.06% of Omeros worth $346,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Susquehanna Fundamental Investments LLC acquired a new position in shares of Omeros during the fourth quarter valued at $1,488,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Omeros during the fourth quarter valued at $1,120,000. Barclays PLC boosted its holdings in shares of Omeros by 121.3% during the third quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock valued at $376,000 after acquiring an additional 51,873 shares during the period. Marshall Wace LLP acquired a new position in shares of Omeros during the fourth quarter valued at $437,000. Finally, Stordahl Capital Management Inc. acquired a new position in shares of Omeros during the fourth quarter valued at $395,000. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Stock Down 18.7%

Shares of NASDAQ OMER opened at $3.21 on Friday. Omeros Co. has a fifty-two week low of $2.97 and a fifty-two week high of $13.60. The firm’s 50-day simple moving average is $7.06 and its 200 day simple moving average is $8.11. The stock has a market cap of $187.16 million, a P/E ratio of -1.39 and a beta of 2.42.

Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.05). On average, sell-side analysts anticipate that Omeros Co. will post -3.09 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on OMER. StockNews.com downgraded shares of Omeros from a “hold” rating to a “sell” rating in a report on Wednesday, April 9th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a report on Friday. Finally, D. Boral Capital restated a “buy” rating and set a $36.00 price objective on shares of Omeros in a research note on Tuesday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.